Technical Indicators Turn Bullish For Catabasis Pharmaceuticals, Inc. (CATB)

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) gained 10.24% in yesterday’s session, going up from its prior closing price of $1.66 to $1.83, and has now recorded rally in 3 consecutive sessions. Many in the market will be closely watching whether this winning streak is sustainable or take a temporary pause for the next couple of trading sessions. The stock price went upward in 4 of the last 10 days and has generated 22% during the last two weeks. The upbeat movement of both volume and price during the recent session is interpreted as a good sign, and, overall 0.99 million more shares exchanged hands compared with prior day. In total, 2.02 M shares exchanged hands for about $3.70 million.

Inside CATB’s Recent Trend

Catabasis Pharmaceuticals, Inc. (CATB) has broken the very wide and strong rising the short-term trend up and an even stronger rising rate is indicated. For any reaction back there will now be support on the roof on the current trend broken at $1.70, a point that may provide a 2nd chance needed to hit a runner. The next trend top is most likely to be exhibited at $2.14 will be the next possible trend-top level and thereby pose a resistance level which may not be broken at the first attempt.

Catabasis Pharmaceuticals, Inc. Technical Signals

CATB has witnessed its long term and short term MA triggering a buy signal. Many traders watch for short-term averages to cross above long-term averages to signal the beginning of an uptrend. Upon corrections, the price will meet support from the averages between $1.62 and $1.36. A break down through these support points will trigger sell signals. Its pivot point low generated buy signal on Monday September 18, 2017, which calls for additional surge until the stock forms a new pivot point high. There was increase in both volume and price. This is usually interpreted as a good sign as traders widely believe rising stock should see increasing volume.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Support And Resistance Levels

In case of pullback, the next support the price will capture from accumulated volume will not be far away from current price at $1.69 and $1.66. It seems to be blessed by the accumulated volume as it meets no resistance above current level and favorable trading conditions will help the stock to show strong performance in the coming days.

It is important to note, however, that the stock needs to make its way through natural risk while testing a key support level. Once this support is broken, another support level will be to be established at a lower level. Turning back to this stock, Catabasis Pharmaceuticals approaches the first support point just current price at $1.69. In case of a break, the next support we will see from accumulated volume is going to be at $1.66 and $1.45.

Catabasis Pharmaceuticals, Inc. (CATB) Risk Assessment

A volatility based measure Bollinger Bands suggests this stock poses high risk. In the most recent session, the stock price hovered around $0.27 between high and low, or 16.88%. The average volatility for the past week stood at 12.86%.

The stock is extremely overbought on RSI14 (77). Normally this will pose a good selling opportunity, but since the stock has broken the trend up the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken.


Previous ArticleNext Article

Related Post

Comparing Valuation And Performance: ContraVir Pha... The shares of ContraVir Pharmaceuticals, Inc. have decreased by more than -31.36% this year alone. The shares recently went up by 7.43% or $0.02 and n...
Financially Devastating or Fantastic? – Equi... The shares of Equity Residential have increased by more than 1.60% this year alone. The shares recently went up by 0.68% or $0.44 and now trades at $6...
Dissecting the Numbers for Huntsman Corporation (H...   Huntsman Corporation (NYSE:HUN) shares are up more than 75.16% this year and recently increased 0.24% or $0.08 to settle at $33.42. Air Prod...
Jounce Therapeutics, Inc. (JNCE) and Chiasma, Inc.... Jounce Therapeutics, Inc. (NASDAQ:JNCE) shares are up more than 88.24% this year and recently increased 2.13% or $0.5 to settle at $24.00. Chiasma, In...
Eaton Corporation plc (ETN) and Okta, Inc. (OKTA) ... Eaton Corporation plc (NYSE:ETN) shares are up more than 1.59% this year and recently increased 0.22% or $0.18 to settle at $80.27. Okta, Inc. (NASDAQ...